PITTSBURGH, May 1, 2024
/PRNewswire/ -- For a seventh time, PANTHERx Rare has been
recognized as the winner of the annual Independent Specialty
Pharmacy Patient Choice Award™, with the announcement made at the
Asembia Specialty Pharmacy Summit this week. Since 2016, the
Managed Markets Insights & Technology (MMIT) Patient Choice
Award has honored the winning specialty pharmacy's exemplary
commitment to patients based on the highest average net promoter
scores (NPS) from the Zitter Insights Specialty Pharmacy Patient
Satisfaction Survey, created to provide independent, objective
benchmarking data across U.S. specialty pharmacies.
PANTHERx was also recognized recently by Drug Channels
Institute as number seven in its ranking by revenue of the top
specialty pharmacies, and as the largest independent specialty
pharmacy in the U.S. Last week the company announced three new
expansions to facilitate its continued growth and enhance its
innovative capabilities to serve more people living with rare and
devastating conditions. What also makes PANTHERx the leader in rare
disease pharmacy is its innovative technology combined with the
continued commitment of its associates in caring for each customer
along their health journey with compassion, empathy, education, and
training that supports their goal of helping individuals with rare
diseases live their best lives.
"Since day one at PANTHERx I have been personally focused on
improving every aspect of the patient experience as the cornerstone
of our success," said PANTHERx Rare CEO and Co-founder Rob
Snyder. "Together we've built a great company that's experiencing
explosive growth, we're investing to continuously enhance the
patient journey, and each day we strive to make our company better
for our patients, caregivers, partners, and investors. We look
forward to collaborating with existing and new pharmaceutical
partners to bring many more life-saving therapies to market for the
people with rare diseases who clearly need them."
About PANTHERx Rare
PANTHERx Rare is a specialty pharmacy purely focused on rare
and orphan diseases, distributing several orphan products and
providing access and support services to those needing them most.
Known as The Rare Disease Pharmacy®, PANTHERx transforms
lives by delivering medicine breakthroughs, clinical excellence,
and access solutions to people living with rare and devastating
conditions. While each rare condition affects few people, together
all rare diseases impact an estimated 25 to 30 million Americans.
Currently over 7,000 rare diseases have been identified and more
than 90% of rare diseases are still without an FDA-approved
treatment. Changes in federal policy and advances in science have
led to a surge in FDA orphan drug approvals, providing tremendous
hope to the rare disease community.
PANTHERx is a dual-accredited specialty pharmacy, holding
distinctions in rare disease including the Accreditation Commission
for Health Care (ACHC) Distinction in Orphan Drugs and Utilization
Review Accreditation Commission (URAC) Rare Disease Center of
Excellence. As a pharmacy focused on patient satisfaction, PANTHERx
is the six-time winner of the prestigious MMIT Patient Choice
Award, including the 2023 honor. PANTHERx is headquartered
in Pittsburgh, Pennsylvania and is licensed in all 50 states and US
territories.
For more information, please
contact marketing@pantherxrare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pantherx-rare-pharmacy-wins-seventh-patient-choice-award-302133534.html
SOURCE PANTHERx Rare Pharmacy